Figure 7. Inhibition of tRCC growth by cabozantinib and rapamycin.
(A) Representative MRI images of Sglt2-Cre; ASPSCR1-TFE3LSL/+ mice with kidney tumor volume measurements (see Methods) at baseline and end of the trial. (B) Waterfall plot with percentage change in overall kidney tumor burden per mouse. (C–E) Representative H&E and IHC (phospho-S6 and Ki-67) at the end of drug trials. N, necrosis; T, tumor. Scale bars: 200 μm (C); 100 μm (D and E).
